Artwork

Content provided by VJOncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by VJOncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Key Trials from ASCO GU 2023 with Scott Tagawa, Karie Runcie, and Tanya Dorff

17:40
 
Share
 

Manage episode 374905005 series 2424442
Content provided by VJOncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by VJOncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode, join GU cancer experts Scott Tagawa (Weill Cornell Medicine and New York Presbyterian, New York City, NY), Karie Runcie (Columbia University Irving Medical Center, New York City, NY), and Tanya Dorff (City of Hope Comprehensive Cancer Center, Duarte, CA) as they discuss the most important clinical trial data for prostate, bladder, and kidney cancer at the ASCO GU Cancers Symposium 2023.

In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).

The post Key Trials from ASCO GU 2023 with Scott Tagawa, Karie Runcie, and Tanya Dorff appeared first on VJOncology.

  continue reading

179 episodes

Artwork
iconShare
 
Manage episode 374905005 series 2424442
Content provided by VJOncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by VJOncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

In this episode, join GU cancer experts Scott Tagawa (Weill Cornell Medicine and New York Presbyterian, New York City, NY), Karie Runcie (Columbia University Irving Medical Center, New York City, NY), and Tanya Dorff (City of Hope Comprehensive Cancer Center, Duarte, CA) as they discuss the most important clinical trial data for prostate, bladder, and kidney cancer at the ASCO GU Cancers Symposium 2023.

In prostate cancer, PARP inhibitors were a hot topic of discussion, with data from TALAPRO-2 (NCT03395197) and TRITON3 (NCT02975934) being presented. In bladder cancer, IMvigor130 (NCT02807636) and TROPHY-U-01 (NCT03547973) were two of the key trials, with additional discussions on antibody-drug conjugates (ADCs), nectin-4-targeted therapies, and the use of molecular profiling in clinical practice. Finally, in kidney cancer, there were updates from ZIRCON (NCT03849118), COSMIC-313 (NCT03937219), and CheckMate 9ER (NCT03141177).

The post Key Trials from ASCO GU 2023 with Scott Tagawa, Karie Runcie, and Tanya Dorff appeared first on VJOncology.

  continue reading

179 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide